Umeclidinium bromide

Umeclidinium bromide
Clinical data
Trade names	Incruse Ellipta
Other names	GSK573719A
License data	EU EMA: by INN;
Pregnancy; category	US: C (Risk not ruled out) ;
Routes of; administration	Inhalation (DPI)
ATC code	R03BB07 (WHO) ; R03AL03 (WHO) (+vilanterol);
Legal status
Legal status	US: ℞-only ; In general: ℞ (Prescription only);
Pharmacokinetic data
Protein binding	~89%[1]
Metabolism	Hepatic (CYP2D6)
Elimination half-life	11 hours
Excretion	Feces (58%) and urine (22%)
Identifiers
	IUPAC name Diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol bromide;
CAS Number	869113-09-7;
PubChem CID	11519069;
ChemSpider	9693857;
KEGG	D10181;
ChEBI	CHEBI:79040;
CompTox Dashboard (EPA)	DTXSID50235966 ;
ECHA InfoCard	100.166.375
Chemical and physical data
Formula	C29H34BrNO2
Molar mass	508.49 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-];
	InChI InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1; Key:PEJHHXHHNGORMP-UHFFFAOYSA-M;

Umeclidinium bromide (trade name Incruse Ellipta) is a long-acting muscarinic antagonist approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD).[1] It is also approved for this indication in combination with vilanterol (as umeclidinium bromide/vilanterol).[2][3]

External links

"Incruse Ellipta (umeclidinium inhalation powder) for Oral Inhalation Use. Full Prescribing Information" (PDF). GlaxoSmithKline, Research Triangle Park, NC 27709. Retrieved 22 February 2016.
Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
"FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.